Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

Thomas Rauch, Ulrike Graefe-Mody, Carolyn F Deacon, Arne Ring, Jens Juul Holst, Hans-Juergen Woerle, Klaus A Dugi, Tim Heise

Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.
Original languageEnglish
JournalDiabetes Therapy
Issue number1
Pages (from-to)10
Publication statusPublished - Nov 2012

ID: 45841462